Overview

Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study will investigate the pharmacokinetics of BAF312 in patients with mild, moderate and severe hepatic impairment compared to healthy control subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Siponimod